Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law Peptides Lack Reliable Safety Information, Watchdog Warns Mitigating Risks of Compounded Drugs Through Surveillance FDA The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law